Overview

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or subcutaneous injection to healthy study participants and following repeat dosing at a single dose level in study participants with atopic dermatitis. Furthermore, the clinical outcome in study participants with atopic dermatitis after administration of UCB9741 by intravenous infusion will be investigated.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
UCB Biopharma SRL